Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975167 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL29569154 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL29569227 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL30087026 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL31127473 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL190685 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL25966 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL4850502 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL29418187 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 | |
| SCHEMBL5692997 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10HIF1ACYP1B1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1011 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-117120422-B | Substituted naphthyl P38 alpha mitogen-activated protein kinase inhibitors | GEN1E生命科学公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125416-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617814-B2 | Neuroactive steroids and methods of use thereof | Sage Therapeutics, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260116912-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116911-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-109010916-B | Moldable formulations containing oxysterol in acellular tissue matrices | 华沙整形外科股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11261211-B2 | 19-NOR neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220056041-A1 | Modified Rhodamine Dye and use Thereof in Biological Assays | Life Technologies Corporation | 2022-02-24 | — | — | US | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| EP-3946606-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2022-02-09 | — | — | EP | disclosed |
| CN-113993846-A | Compositions and methods for treating pain and/or inflammation | 诺门图姆股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229621-B2 | Pharmaceutical compositions of dimethyl fumarate | ARBOR PHARMACEUTICALS, LLC (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | ALDH1A1 2152/4885HSD17B10 3952/4885HIF1A 1828/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | ALDH1A1 3991/4885HSD17B10 1178/4885HIF1A 1384/4885 |
| US-11229621-B2 | Pharmaceutical compositions of dimethyl fumarate | FH, SDHB, SDHA | ALDH1A1 2404/4885HSD17B10 870/4885HIF1A 750/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ALDH1A1 3293/4885HSD17B10 856/4885HIF1A 3211/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | ALDH1A1 383/4885HSD17B10 979/4885HIF1A 2858/4885 |
| US-20220056041-A1 | Modified Rhodamine Dye and use Thereof in Biological Assays | QTRT1, MRPL21, RRP1B | ALDH1A1 1889/4885HSD17B10 4054/4885HIF1A 3982/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | ALDH1A1 1953/4885HSD17B10 1136/4885HIF1A 3662/4885 |
| US-20260116912-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SCN4A, CHRNA4, CACNG4 | ALDH1A1 1606/4885HSD17B10 1500/4885HIF1A 2182/4885 |
| US-12617814-B2 | Neuroactive steroids and methods of use thereof | HSD3B1, HSD3B2, NR3C2 | ALDH1A1 958/4885HSD17B10 383/4885HIF1A 1732/4885 |
| US-20260116911-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SCN4A, CACNG4, SLC6A4 | ALDH1A1 1610/4885HSD17B10 1409/4885HIF1A 2156/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | ALDH1A1 1251/4885HSD17B10 1519/4885HIF1A 2814/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | ALDH1A1 1334/4885HSD17B10 3285/4885HIF1A 4336/4885 |
| US-11261211-B2 | 19-NOR neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, NR3C1 | ALDH1A1 257/4885HSD17B10 279/4885HIF1A 549/4885 |
| US-20260125416-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | HSD3B1, HSD3B2, HSD11B1 | ALDH1A1 451/4885HSD17B10 55/4885HIF1A 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.